# Velo3D

Type: Company (VLD)

Source: GetYourBrief — https://getyourbrief.com/entity/velo3d
Canonical HTML page: https://getyourbrief.com/entity/velo3d

## Recent coverage (2 stories, network-wide)

### Biotech Volatility and Mixed Earnings Define Q4 Market Landscape
2026-02-18 07:27:37 · Sector: saas · Sentiment: Strongly positive · Impact: 7/10 · Sources: 28

A wave of Q4 earnings reports reveals a tightening fiscal environment for major players like Genmab and Santos, even as specialized biotech firms see massive gains from clinical breakthroughs. Market reactions remain erratic, with several companies experiencing share price declines despite meeting or exceeding operational targets.
Full story: https://getsaasbrief.com/story/genmab-earnings-biotech-volatility-q4-2026

### Biotech Volatility and Earnings Pressures Define Mixed Market Session
2026-02-17 20:11:41 · Sector: finance · Sentiment: Strongly positive · Impact: 7/10 · Sources: 9

The equity markets are navigating a complex landscape of 'sell-the-news' reactions and extreme biotech volatility following a series of clinical and financial updates. While Compass Pathways surged on positive trial results, Ocular Therapeutix and Genmab faced significant selling pressure despite reaching key milestones.
Full story: https://getfinancebrief.com/story/genmab-profit-drop-biotech-volatility-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.